Objective: To investigate the benefits of the focal use of botulinum toxin in spasticity in the forearm seen after incomplete spinal cord injury.
Design: A single case study with standardized assessment before and at three-week intervals after injection.
Intervention: EMG-guided selective injection of botulinum toxin.
Subject: A 23-year-old man, 18 months post injury.
Measures: Rivermead Motor Assessment; grip strength; Jebsen hand tests; visual analogue scale; Ashworth spasticity scale.
Results: Weakness was seen as expected with some functional losses, but the patient made gains in the areas of concern: shaking hands, typing, using the hand to drink. These gains were sustained at 12 weeks.
Conclusion: Selective use of botulinum toxin to weaken muscles can lead to functional benefit.
Get full access to this article
View all access options for this article.
References
1.
Lance JWPathophysiology of spasticity and clinical experience with baclofen. In: Feldman RG.Young RR, Koella WP eds. Spasticity: Disordered motor control. London: Year Book Medical Publishers, 1980: 185-204.
2.
Brown P.Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry1994; 57: 773-77.
3.
Edwards S.The incomplete spinal cord injury. In: Bromley Ida ed. Tetraplegia and paraplegia: a guide for physiotherapists . Edinburgh: Churchill Livingstone , 1991: 145-66.
4.
Dietz V., Quintern J., Berger W.Electrophysiological studies of gait in spasticity and rigidity: Evidence that altered mechanical properties of muscle contribute to hypertonia. Brain1981; 104: 431-49.
5.
Berger W., Horstmann G., Dietz V.Tension development and muscle activation in the leg during gait in spastic hemiparesis: Independence of muscle hypertonia and exaggerated stretch reflexes . J Neurol Neurosurg Psychiatry1984; 47: 1029-33.
Simpson DM, Alexander DN, O'Brien CF et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology1996; 46(5): 1306-10.
8.
Dengler R., Neyer U., Wohifarth K., Bettig U., Janzik HHLocal botulinum toxin in the treatment of spastic drop foot. J Neurol1992; 239(7): 375-78.
9.
Anderson TJ, Donaldson IMBotulinum toxin; one man's poison is another man's potion. N Z Med J1995; 108: 307-308.
10.
Hesse S., Krajnik J., Luecke D., Jahnke MT, Gregoric M., Mauritz KHAnkle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke1996; 27(3): 455-60.
11.
Mathiowetz V., Weber K., Volland G., Kashman N.Reliability and validity of grip and pinch strength evaluations. J Hand Surg Am1984; 92: 222-26.
12.
Ashworth B.Preliminary trial of cariosoprodal in multiple sclerosis. Practitioner1964; 192: 540.
13.
Norkin CC, White DJMeasurement of joint motion. A guide to goniometry, second edition. Philadelphia: FA Davies; 1995.
14.
Jebsen RH, Trieschmann R., Trotter N., Howard LAAn objective and standardised test of hand function. Arch Phys Rehabil1969; 50: 311-19.
15.
Lincoln NB, Leadbetter D.Assessment of motor function in stroke patients. Physiotherapy1979; 65: 48-51.
